The Effect of Metformin on Breast Cancer Patients

• Status: Recruiting
• Trial end date: 2020-10-01
• Target enrollment: 0
• Participant gender: Female

Summary

Several clinical trials have addressed the promising anticancer effect of metformin on the survival benefits, clinical response, and pathological response of breast cancer patients.

Therefore, this study will assess the anticancer effect of metformin when added to the neoadjuvant chemotherapy protocol of non-diabetic breast cancer patients. In addition to, the impact of metformin addition to the neoadjuvant chemotherapy on the quality of life of breast cancer patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beni-Suef University
• Collaborator: Ahram Canadian University
• Treatments: Cyclophosphamide; Doxorubicin; Metformin; Paclitaxel

Criteria

Inclusion Criteria:

1. Non-diabetic breast cancer patients, receiving neoadjuvant chemotherapy treatment.

2. Female Age between 18- 65 years.

3. Written informed consent.

Exclusion Criteria:

1. Known hypersensitivity reaction to Metformin.

2. Intolerable Metformin GI complaints.

3. Patients at risk of lactic acidosis.

4. Diabetic breast cancer patients.

5. Body Mass Index < 18.5 (underweight breast cancer patients).

6. Renal impairment, eGFR <45 mL/min/1.73 m².